阿帕替尼片治疗晚期胃癌的临床研究

发布时间：2018-06-09 06:24

本文选题：阿帕替尼片 + 替吉奥胶囊　；参考：《中国临床药理学杂志》2017年07期

【摘要】：目的观察阿帕替尼片联合替吉奥胶囊和奥沙利铂注射剂治疗晚期胃癌的临床疗效和安全性。方法将90例晚期胃癌患者随机分为对照组45例和试验组45例。对照组予以第1天奥沙利铂130 mg·m~(-2),静脉滴注2 h+口服替吉奥,体表面积1.25 m~2的患者,每次40 mg,体表面积1.25~1.5 m~2的患者,每次50 mg,体表面积1.5 m~2的患者,每次60 mg,早晚餐后各一次,连用14 d。试验组在对照组治疗的基础上,予以口服阿帕替尼850 mg,qd,餐后0.5 h服用。2组患者1个疗程均为3周,共治疗4个疗程。比较2组患者的临床疗效和药物不良反应的发生情况。结果治疗后,试验组和对照组的客观缓解率分别为40.00%(18/45例)和24.44%(11/45例),疾病控制率分别为77.78%(35/45例)和64.44%(29/45例)差异均有统计学意义(P0.05)。试验组和对照组恶心呕吐发生率分别为11.11%,13.33%;粒细胞减少发生率分别为11.11%,8.89%;腹泻发生率均为2.22%;手足综合征发生率均为4.44%;血小板下降发生率分别为8.89%,6.67%差异均无统计学意义(P0.05)。试验组和对照组乏力发生率分别为2.22%,11.11%;高血压发生率分别为2.22%,11.11%;蛋白尿发生率分别为0,6.67%差异均有统计学意义(P0.05)。结论阿帕替尼片联合替吉奥胶囊和奥沙利铂注射剂治疗晚期胃癌的临床疗效显著,且安全性较高。
[Abstract]:Objective to observe the clinical efficacy and safety of apatinib combined with tigio capsule and oxaliplatin injection in the treatment of advanced gastric cancer. Methods 90 patients with advanced gastric cancer were randomly divided into control group (n = 45) and trial group (n = 45). The control group was treated with oxaliplatin 130 mg / mO-2 on the first day. The patients with a surface area of 1.25 mm2 were treated with oral tetracycline for 2 hours. The patients with surface area of 1.25 mm2 were treated with 50 mg of oxaliplatin and 1.5 mg / 2 of body surface area once every morning and evening after meal, and the control group was treated with 50 mg of oxaliplatin and 1.5 mg / 2 of body surface area once each morning and evening after meal. Continuous use for 14 days. On the basis of the treatment in the control group, the experimental group was given oral Apatinib 850 mg / g QD. The patients in the 2 groups were given one course of treatment for 3 weeks at 0.5 h after meal, with a total of 4 courses of treatment. The clinical efficacy and adverse drug reactions were compared between the two groups. Results after treatment, the objective remission rates of the experimental group and the control group were 40.0018 / 45 and 24.44 / 11 / 45, respectively. The disease control rate was 77.7835 / 45 and 64.4445 / 45 respectively. There were significant differences between the two groups (P 0.05). The incidence of nausea and vomiting in the test group and the control group were 11.11 and 13.33, respectively; the incidence of granulocytopenia was 11.11 and 8.89; the incidence of diarrhea was 2.22; the incidence of hand and foot syndrome was 4.44; the incidence of thrombocytopenia was 8.89 and 6.67% respectively. There was no significant difference in the incidence of granulocytopenia (P 0.05). The incidence of fatigue was 2.22% in the test group and 11.11% in the control group. The incidence of hypertension was 2.22% and 11.11%, respectively. The incidence of proteinuria was 0.6.67%. There were significant differences in the incidence of proteinuria between the two groups (P 0.05). Conclusion Apatinib combined with teguio capsule and oxaliplatin injection is effective and safe in the treatment of advanced gastric cancer.
【作者单位】：成都医学院第一附属医院肿瘤科;新都区中医院妇科;四川省人民医院呼吸内科;
【基金】：四川省科技基金资助项目(120078)
【分类号】：R735.2

【参考文献】